Start low to stay long: adapted dose escalation as a patient-centered strategy for adjuvant Abemaciclib

Stefan Lukac

Open source

DOI
10.21037/tbcr-2026-0039
Published
2026-10
Container
Translational Breast Cancer Research
Publisher
AME Publishing Company
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.21037/tbcr-2026-0039,
  title = {Start low to stay long: adapted dose escalation as a patient-centered strategy for adjuvant Abemaciclib},
  author = {Stefan Lukac},
  year = {2026},
  journal = {Translational Breast Cancer Research},
  doi = {10.21037/tbcr-2026-0039},
  url = {https://doi.org/10.21037/tbcr-2026-0039}
}

RIS

TY  - JOUR
TI  - Start low to stay long: adapted dose escalation as a patient-centered strategy for adjuvant Abemaciclib
AU  - Stefan Lukac
PY  - 2026
JO  - Translational Breast Cancer Research
DO  - 10.21037/tbcr-2026-0039
UR  - https://doi.org/10.21037/tbcr-2026-0039
ER  - 

APA

Lukac, S. (2026). Start low to stay long: adapted dose escalation as a patient-centered strategy for adjuvant Abemaciclib. Translational Breast Cancer Research. https://doi.org/10.21037/tbcr-2026-0039

Source records